8-K

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                             CURRENT REPORT PURSUANT
                          TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


       Date of report (Date of earliest event reported): February 6, 2002


                         AMERICAN BIO MEDICA CORPORATION
                -------------------------------------------------
             (Exact Name of Registrant as Specified in its Charter)

           New York                       0-28666              14-1702188
- ----------------------------            ------------      ----------------------
(State or Other Jurisdiction            (Commission           (IRS Employer
      of Incorporation)                 File Number)      Identification Number)



          122 Smith Road, Kinderhook, NY                      12106
          ---------------------------------------------------------
          (Address of Principal Executive Offices)      (Zip Code)

       Registrant's telephone number, including area code: (800) 227-1243











ITEM 5.      OTHER EVENTS

             On February 6, 2002, the Board of Directors of the registrant
accepted the resignation of Robert L. Aromando as President and Chief Executive
Officer. Aromando will remain a Director of the registrant. Gerald Moore, the
registrant's current Chairman of the Board of Directors, was appointed to the
position of President and Chief Executive Officer of the registrant. Moore also
remains the registrant's Chairman of the Board of Directors.

ITEM 7.  FINANCIAL STATEMENTS, PRO FORMA FINANCIAL STATEMENTS AND EXHIBITS.

         (c)     Exhibits.

                  The following exhibits are filed with this report on Form 8-K:

                  99.1      American Bio Medica Corporation press release dated
                            February 7, 2002











                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                           AMERICAN BIO MEDICA CORPORATION
                                           (Registrant)


Dated:  February 7, 2002                   By:      /s/ Keith E. Palmer
                                                ----------------------------
                                                    Keith E. Palmer
                                                    Chief Financial Officer









                                  Exhibit Index


Exhibit No.                  Description                          Page No.
- -----------                  -----------                          --------

99.1              American Bio Medica Corporation press              5
                  release dated February 7, 2002

EX-99

                                                                    Exhibit 99.1



FOR IMMEDIATE RELEASE:

                  GERALD MOORE APPOINTED ABMC PRESIDENT AND CEO
                  ---------------------------------------------
            Company Chairman Had Assumed Acting CEO Responsibilities
                          from Robert L. Aromando Jr.

KINDERHOOK, NY, February 7, 2002 - American Bio Medica Corporation (NASDAQ:
ABMC) today announced that its board of directors has officially appointed
Gerald Moore president and chief executive officer. Moore succeeded Robert L.
Aromando Jr. as acting president and CEO when Aromando requested a leave of
absence in December 2001. Aromando officially resigned his positions January 31,
2002. Moore was appointed president and CEO by a unanimous vote of the ABMC
board during a board meeting yesterday.

Aromando remains an ABMC director and consultant for strategic business
development. Moore also retains his position as chairman of the ABMC board of
directors.

"This is a seamless transition, one that allows me to focus attention on
managing ABMC with full authority, and also allows Bob Aromando to remain
affiliated with the company, but focus most of his attention on the matters for
which he requested a leave," said Moore. "I am grateful for this opportunity and
am quite optimistic about ABMC's future."

Moore brings prior experience as a chief executive to ABMC, as well as an
extensive background in international health care marketing and sales.

He was most recently president and CEO of Med-Ox Diagnostics of Canada, and
president of BioSys, Inc. From 1990 until 1998, Moore was president of UNIPATH
(North America), a division of worldwide food, home care and personal care
conglomerate Unilever. Under Moore's leadership UNIPATH became a preeminent
leader in the clinical health care markets in Canada and the United States.

Moore is a member of the board of directors of the Canadian Association of
Clinical Microbiology and Infectious Diseases (CACMID), a director of the
Canadian Clinical Standards organization and he serves on the liaison board of
exhibitors to the Interscience Conference on Antimicrobial Agents and
Chemotherapy (ICAAC) of the American Society of Microbiology. Moore earned a
degree in chemistry and mathematics from Strathclyde University in Glasgow,
Scotland, in 1961.

In his first conference call with ABMC investors in December, Moore outlined his
priorities for managing ABMC -- specifically, developing strategic business in
the workplace and clinical markets, creating new products and streamlining
operations. Since Moore has become acting president and chief executive officer,
ABMC has announced that it has entered into a distribution agreement with Quest
Diagnostics, Inc. (NYSE:DGX), making ABMC Quest Diagnostics' exclusive
manufacturer of urine based point-of collection drug testing devices, earned
preferred vendor status with Express Personnel and applied for FDA clearance of
its proprietary on-site drug test for Oxycodone.

                                     (more)






About American Bio Medica Corporation

American Bio Medica Corporation develops, manufactures and markets inexpensive,
accurate, on-site drugs-of-abuse diagnostic kits, sprays and support services
worldwide. The company's global distributors target the workplace, physicians,
corrections, clinical, and educational markets. ABMC's Rapid Drug Screen(R) and
OralStat6(TM) test for the presence or absence of drugs of abuse in urine and
saliva, respectively, while its Drug Detector(TM) identifies minute traces of
illegal drugs on surfaces. ABMC was recently listed among the top ten
biotechnology companies on the Deloitte & Touche 2001 Technology Fast 500, a
ranking of the fastest growing companies in North America.

Forward-looking statements in this release are made pursuant to the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that such forward-looking statements involve risk and
uncertainties, including without limitation, continued acceptance of the
Company's products, increased levels of competition for the Company, new
products and technological changes, intellectual property rights and other risks
detailed from time to time in the Company's periodic reports filed with the
Securities and Exchange Commission.



                                      # # #